Zydus France Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Zydus France Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus France — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Zydus France?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$650.0K	14	68.6%
Zydus Lifesciences Limited	$196.9K	6	20.8%
Unison Pharmaceuticals Private Limited	$65.7K	5	6.9%
Cadila Healthcare Limited	$34.7K	1	3.7%

Zydus France sources from 4 verified Indian suppliers across 16 distinct formulations. The supply base is diversified across 4 suppliers, reducing single-source dependency risk.

What Formulations Does Zydus France Import?

Formulation	Value	Ships
Drugs and pharmaceuticals harmlessmedicines emtricitabine and tenofovir disoproxil film coated tablets	$300.0K	6
Drugs and pharmaceuticals harmlessmedicines emtricitabine and tenofovir disoproxil film coated tablets	$200.0K	4
Tramadol teva er tabs 100 MG tablets (tramadol hydrochloride) (export authorization no. : p-exp-11236/2024 date -	$107.6K	3
Medicines. emtricitabine 200MG +	$50.0K	1
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets 200 MG/ 245 MG	$50.0K	1
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets (200 MG/ 245 MG)	$50.0K

What Products Does Zydus France Import?

Top Products by Import Value

1Emtricitabine$600.0K 2Tenofovir$500.0K

Zydus France Therapeutic Categories — 1 Specializations

Zydus France imports across 1 therapeutic categories, with Antiviral & HIV Medications (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Antiviral & HIV Medications

2 products · 100.0% · $1.1M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Emtricitabine	Antiviral & HIV Medications	$600.0K	12	0.5%	4
2	Tenofovir	Antiviral & HIV Medications	$500.0K	10	0.0%

Key Metrics

Total Import Value$1.1M

Products2

Shipments22

Categories1

CountryFrance

#1 Rankings0

Indian Suppliers4

Formulations16

Top Categories

Antiviral & HIV Medications100.0%

Indian Suppliers

Last updated: March 28, 2026

Zydus France — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zydus France is a pharmaceutical importer and distributor based in Nanterre, Île-de-France, operating as a 100% subsidiary of Zydus International Private Limited, Ireland, which is ultimately owned by Cadila Healthcare Limited, headquartered in Ahmedabad, India. Established in 2003, Zydus France focuses on the importation and distribution of generic pharmaceutical products within the French market. The company offers a diverse portfolio, including tablets, ointments, and syrups, catering to various therapeutic areas.

As part of the Zydus Lifesciences Limited group, Zydus France benefits from the parent company's extensive global presence and manufacturing capabilities. Zydus Lifesciences ranks fourth in the Indian pharmaceutical industry and has a strong presence in regulated markets such as the US and Europe, including France and Spain. This affiliation enables Zydus France to leverage the group's research and development resources, ensuring access to a broad range of high-quality generic medications.

2Distribution Network

Zydus France operates its distribution network from its headquarters in Nanterre, Île-de-France. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in the Paris metropolitan area suggests efficient access to major transportation hubs, facilitating nationwide distribution. The French pharmaceutical market is well-developed, with a robust infrastructure supporting the distribution of pharmaceutical products across the country. Zydus France's affiliation with Zydus Lifesciences Limited, which has manufacturing sites and research facilities in India, the US, and Brazil, likely supports its import operations, ensuring a steady supply of products to meet market demand.

Supplier Relationship Intelligence — Zydus France

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Zydus France's sourcing strategy exhibits a notable concentration, with a significant portion of its imports originating from a single supplier, MACLEODS PHARMACEUTICALS LIMITED. This supplier accounts for approximately 68.6% of the total import value, amounting to $650,000 across 14 shipments. The remaining imports are distributed among three other suppliers: ZYDUS LIFESCIENCES LIMITED (20.8%), UNISON PHARMACEUTICALS PRIVATE LIMITED (6.9%), and CADILA HEALTHCARE LIMITED (3.7%). This concentration indicates a strategic choice to maintain strong partnerships with key suppliers, potentially ensuring favorable terms and consistent product quality.

However, such dependency on a single supplier can pose risks, including supply chain disruptions due to unforeseen events affecting that supplier. The limited number of suppliers also suggests a lack of diversification, which could impact Zydus France's ability to adapt to market changes or shifts in supplier capabilities. To mitigate these risks, it would be prudent for Zydus France to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing potential vulnerabilities.

2Supply Chain Resilience

Zydus France's supply chain resilience is closely tied to its sourcing strategy. The heavy reliance on MACLEODS PHARMACEUTICALS LIMITED for the majority of imports indicates a concentrated supply chain, which may be susceptible to disruptions. The limited number of suppliers—four in total—suggests a lack of diversification, potentially affecting the company's ability to adapt to changes in the market or supply chain dynamics.

To enhance resilience, Zydus France could consider expanding its supplier network, incorporating additional manufacturers to distribute risk and ensure a more robust supply chain. Additionally, evaluating the regulatory compliance and manufacturing standards of existing suppliers is essential to maintain product quality and meet French regulatory requirements. Ensuring that suppliers adhere to recognized Good Manufacturing Practices (GMP) and other relevant standards will contribute to the overall stability and reliability of the supply chain.

3Strategic Implications

Zydus France's current sourcing pattern, characterized by a high dependency on MACLEODS PHARMACEUTICALS LIMITED, may offer short-term benefits such as favorable pricing and streamlined logistics. However, this concentration poses strategic risks, including potential supply chain disruptions and limited flexibility in responding to market changes. For Indian exporters, this presents an opportunity to engage with Zydus France by offering alternative products or formulations that complement the existing portfolio, thereby reducing the risk associated with supplier concentration.

By diversifying its supplier base, Zydus France can enhance its competitive position in the French market, ensuring a more resilient and adaptable supply chain. Indian exporters can leverage this opportunity by demonstrating the quality and reliability of their products, aligning with Zydus France's commitment to providing high-quality generic medications to the French healthcare system.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of health products available in the French market. Key legislation governing pharmaceutical imports includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation, and distribution of pharmaceutical products.

For Indian generics to be marketed in France, they must obtain a marketing authorization from ANSM. This process involves submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy. The dossier must include detailed information on the manufacturing process, quality control measures, and clinical data supporting the product's therapeutic indications. Once approved, the product is granted a marketing authorization number, allowing it to be legally marketed and distributed within France.

2Import Licensing & GMP

Import licensing requirements in France stipulate that pharmaceutical products must be accompanied by a valid marketing authorization issued by ANSM. Additionally, importers must ensure that their suppliers comply with recognized Good Manufacturing Practices (GMP), such as EU GMP, WHO GMP, or PIC/S standards. This compliance ensures that imported products meet the necessary quality standards and are safe for patient use.

Wholesale distribution authorization is also required for entities involved in the distribution of pharmaceutical products within France. This authorization ensures that distributors adhere to regulatory standards concerning storage, handling, and transportation of pharmaceutical products, maintaining their quality and integrity throughout the supply chain.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to verify their quality, potency, and purity before being released into the French market. Stability studies are also required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in French, detailing the product's composition, dosage instructions, storage conditions, and expiration date. Serialization mandates may also apply, requiring unique identifiers on packaging to facilitate traceability and prevent counterfeit products from entering the supply chain.

4Recent Regulatory Changes

Between 2024 and 2026, France has implemented several regulatory changes affecting pharmaceutical imports, particularly concerning the approval process for generic medications. These changes aim to streamline the marketing authorization process, reduce approval times, and enhance the availability of generic drugs in the French market. Additionally, there has been an increased emphasis on ensuring the traceability of pharmaceutical products through serialization and enhanced reporting requirements for adverse drug reactions.

TransData Nexus Research · France regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Zydus France identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Zydus France's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 22 individual customs records matching Zydus France.
5.Supplier Verification: Zydus France sources from 4 verified Indian suppliers across 16 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Zydus France

Zydus France — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Zydus France?

What Formulations Does Zydus France Import?

What Products Does Zydus France Import?

Top Products by Import Value

Zydus France Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Zydus France — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Zydus France

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into France — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Zydus France — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Frequently Asked Questions — Zydus France

What products does Zydus France import from India?

Who supplies pharmaceuticals to Zydus France from India?

What is Zydus France's total pharmaceutical import value?

What therapeutic categories does Zydus France focus on?

Get Full Zydus France Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology